Skip to main content
R&I

Discover what's new in R&I

Two labelled projects, one project launched and two calls in progress

Two labelled projects have been added to the cluster's project portfolio

CardiAmmonia (call 26) was awarded the label last June and falls under the theme of radiation applied to health. The coordinating companyIBA, in partnership with Elysia-Raytest, the University of Liège and the University of Louvain, aims to develop the next generation of radioisotope production solutions for cardiac imaging applications. This labelled project is the result of a co-porting by the MecaTech and BioWin clusters. The 27-month project, with a budget of €3 million, will start in January 2020.

Aeronext (call 25) was awarded the label last November. It falls under the themes of biopharma and medical devices. Coordinated by Aquilon Pharma, the project aims to develop innovative inhalation therapies for the treatment of asthma and chronic obstructive pulmonary disease. The objective of the combination of an innovative formulation and device is to improve the deposition rate of the active ingredient in the lungs by 3 to 6 times compared to current treatments. To carry out this 48-month project with a budget of €4.5 million, Aquilon Pharma will collaborate with three other partners: Simonis Plastic, the CER research centre and the University of Liège.  The project is scheduled to start in February 2020.

New project in progress 

Launch of the MODULAR 01 project (Call 25) on 23 October in the new premises of OOC/ORA. This project, which was approved last April, falls under the theme of radiation applied to health. Its objective is to develop a new generation synthesizer dedicated to the production of radiopharmaceuticals for imaging and therapy. The partner companies OOC/ORA Nucleis will work in collaboration with the University of Liège and the University of Namur. 
The project has a budget of €3.1 million and will last 3 years. 

Calls in progress (Calls 28 and 29)

Under call 28, only one project (FAR) in the field of radiation applied to health will be proposed for labelling. The decision is expected in the first quarter of 2020. 

Call 29 is in progress according to a new assembly procedure developed in cooperation between the stakeholders (clusters, administrations, panel, government). The Bio-Shield project, in the field of biopharmaceutical innovations, will inaugurate this new procedure. 

A new assembly procedure developed in cooperation between the stakeholders (clusters, administrations, panel, government)